Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus was awarded a new funded grant from the U.S. FDA to validate best practices for PBBM/PBPK modeling workflows to simulate VBE studies.

Simulations Plus Receives New FDA Grant Award

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus hosted its first University+ PBPK Summer Camp, an intensive 8-week PBPK modeling course for more than 80 attendees from 26 countries.

Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors

LANCASTER, Calif.--(BUSINESS WIRE)--Dr. Viera Lukacova, Chief Science Officer of Simulations Plus, was selected to be a Fellow of the American Association of Pharmaceutical Scientists.

Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)

LANCASTER, Calif.--(BUSINESS WIRE)--The July 2023 issue of Clinical Pharmacology & Therapeutics published research where DILIsym was used to predict liver safety of CBD & VPA treatments.

Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of ADMET Predictor 11 with significant enhancements expressly designed to accelerate drug discovery research.

Simulations Plus Releases ADMET Predictor® 11

Simulations Plus' (SLP) third-quarter fiscal 2023 top line is driven by higher revenues in the Software and Services business segments.

Simulations Plus (SLP) Q3 Earnings Miss, Revenues Rise Y/Y

Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2023 Earnings Conference Call July 6, 2023 5:00 PM ET Company Participants John Wilfong - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum David Larsen - BTIG Yuan Zhi - B. Riley Francois Brisebois - Oppenheimer Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2023 Financial Results Conference Call.

Simulations Plus, Inc. (SLP) Q3 2023 Earnings Call Transcript

Simulations Plus (SLP) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.20 per share a year ago.

Simulations Plus (SLP) Q3 Earnings Miss Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported revenue growth in the 3rd quarter of FY23 with 3Q revenue up 9% to $16.2 million; 9mo revenue up 4% to $43.9 million.

Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results

Simulations Plus' (SLP) third-quarter performance is likely to have gained from the healthy adoption of its solutions across various verticals amid continued macroeconomic weakness.

Simulations Plus (SLP) to Report Q3 Earnings: What's in Store?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call and webcast on July 6, 2023, at 5pm EDT to discuss the financial results from the 3rd quarter of FY2023.

Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today the acquisition of Immunetrics, Inc., an addition of important and proven QSP technology in new therapeutic areas.

Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities

Tencent Music Entertainment Group 

Ternium

Epsilon Energy Ltd

Gulf Resources

Inmode Ltd

NuScale Power Corp

While it's a general rule of thumb that you get what you pay for, in the market, you can sneak in some overlooked compelling discounts, which might be the case with the below best affordable stocks to invest in. With a price tag under $50, these enterprises facilitate approachability while also delivering on the quality or relevance components.

7 Stocks Under $50 to Buy (and Never Sell)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today the release of a targeted package of software and services for accelerating pulmonary drug discovery and development.

Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes

Simulations Plus, Inc. is a company that develops software for drug discovery and development using artificial intelligence and machine learning technology. SLP has seen what was very impressive growth begin to quickly slow.

Simulations Plus: Overhyped With No Growth Left

Asure Software

Atlassian

Zscaler

Investors can consider adding four low-beta tech stocks like TEAM, ZS, SLP and ASUR in their portfolios to hedge against a highly-volatile market.

4 Low-Beta Tech Stocks to Hedge Against Market Uncertainty

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA renewed licenses to DILIsym, its flagship QST software, ensuring the agency's continued access for another year.

Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses

The mean of analysts' price targets for Simulations Plus (SLP) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Simulations Plus (SLP) Climb 53.66% to Reach the Level Wall Street Analysts Expect?

Simulations Plus' (SLP) Q2 results are driven by higher revenues in Software and Services business segments.

Simulations Plus (SLP) Q2 Earnings Beat, Revenues Up Y/Y

Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2023 Earnings Conference Call March 5, 2023 5:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants François Brisebois - Oppenheimer Matt Hewitt - Craig-Hallum Mitra Ramgopal - Sidoti Dane Leone - Raymond James Operator Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Simulations Plus, Inc. (SLP) Q2 2023 Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of 11.11% and 2.54%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Surpasses Q2 Earnings Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reported revenue growth in the 2nd quarter of FY23 with total 2Q revenue up 6% to $15.8 million; YTD revenue up 2% to $27.7 million.

Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results

Simulations Plus' (SLP) second-quarter performance is likely to gain from the healthy adoption of its solutions across various verticals.

Simulations Plus (SLP) to Report Q2 Earnings: What's in Store?

Simulations Plus (SLP) will be working on the development of QSAR models by utilizing information available from both academic/patent literature and SACF to test effectiveness against MTHFD2.

Simulations Plus (SLP) Joins SACF to Develop Anticancer Drugs

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus collaborates with the Sino-American Cancer Foundation to use its AIDD technology & expertise to discover new anticancer therapies.

News for Simulations Plus Stock (SLP)